Friday, 02 October 2020
Scientists have created a three-dimensional (3D) tumour model in the laboratory for ovarian cancer that could lead to improved understanding and treatment of the disease.
The international team, led by the 糖心原创 and Queen Mary University London have created a multicellular 3D microenvironment that recreates the way tumour cells grow in ovarian cancer and respond to chemotherapy drugs. The research has been published today in Science Advances.
There is a need for improved 3D cancer models to study tumour growth and progression in patients and test responses to new treatments. At present, 90% of successful cancer treatments tested pre-clinically fail in the early phases of clinical trials and less than 5% of oncology drugs are successful in clinical trials. Pre-clinical tests mostly rely on a combination of two-dimensional (2D) lab grown cell cultures and animal models to predict responses to treatment.
However, conventional 2D cell cultures fail to mimic key features of tumour tissues and interspecies differences can result in many successful treatments in animal hosts being ineffective in humans. Consequently, novel experimental 3D cancer models are needed to better recreate the human tumour microenvironment and incorporate patient-specific differences.
Cancer spheroids made from triple cultures including ovarian cancer cells, endothelial cells, and mesenchymal stem cells growing within the peptide-protein co-assembling material.
The new hydrogel biomaterial is made by the co-assembly of peptides with proteins found in ovarian cancer. The mechanism of formation enables the peptides to assemble these proteins into molecular environments, emulating how they are presented in the patient tumour.
Professor Alvaro Mata, from the 糖心原创’s School of Pharmacy led the study, said: “Bioengineered self-assembling matrices expand our experimental repertoire to study tumour growth and progression in a biologically relevant, yet controlled, manner. In this study we used peptide amphiphiles to co-assemble with extracellular matrix proteins into tuneable 3D models of the tumour microenvironment. The peptide/protein composite matrix was designed to attempt to resemble physical, biomolecular, and cellular features of tumours present in patients. We tested the response of the lab grown tumours using chemotherapeutics to validate the functionality of the multicellular constructs and saw the tumour shrink. This suggests that the new peptide/protein/cellular biomaterial could lead to more effective testing of new drugs and treatments for ovarian cancer.”
Self-assembly is the process by which multiple components can organise into larger well-defined structures. Biological systems rely on this process to controllably assemble molecules and cells into complex and functional tissues with the remarkable properties that we know of such as the capacity to grow, replicate, and perform robust functions.
Associate Professor Daniela Loessner, from Monash University in Australia and co-author of the study says: “Currently, the gold standard for 3D cancer models is the commercially available MatrigelTm, a solubilized basement membrane extracted from mouse sarcoma. A major reason for Matrigel’s popularity is its capacity to enable cell-matrix interactions, which promote the growth of cancer and stromal cells into aggregates known as spheroids. However, it lacks control in mimicking the tumour microenvironment due to its batch variability, undefined composition, and animal origin. These features are important limitations to effectively screen and develop new treatments for cancer. Our research has demonstrated the capacity to engineer a 3D matrix that can serve as a complex, yet controllable, alternative to Matrigel.”
Story credits
More information on the is available from Professor Alvaro Mata on a.mata@nottingham.ac.uk or Jane Icke Media Relations Manager at the 糖心原创, on 0115 74 84417, jane.icke@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.